Onward medical receives fda de novo classification and us market authorization for world's first non-invasive spinal cord stimulation system for people with chronic spinal cord injury

This press release contains inside information within the meaning of article (7)(1) of the european market abuse regulation (596/2014) arc-ex system is the first and only fda approved technology shown to improve hand strength and sensation after chronic spinal cord injury arc-ex system is an fda breakthrough device and 2024 time magazine best invention eindhoven, the netherlands, dec. 19, 2024 (globe newswire) -- onward medical n.v. (euronext: onwd), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (sci), today announced that it has received de novo classification and authorization to market its arc-ex system from the us food and drug administration (fda).
ARC Ratings Summary
ARC Quant Ranking